04.28.25 -- Global Licensing, Pharma Sovereignty, And Biopharma Innovation Trends

We know how tough it can be to find the right CDMO, especially when capacity is tight and timelines are critical. That's why you’ll find our collection of recent Outsourced Pharma Capacity Update presentations so valuable. Our April Partners Week Update details the latest capabilities and available capacity from 40 leading CDMOs – and you can experience it all from the convenience of your screen. View the on-demand sessions for the modalities that fit your needs.

Pharmaceutical sovereignty is no longer a theoretical concern. Sovereignty in this context does not imply isolation, but rather strategic resilience: building robust national and regional capabilities that ensure security while enabling global collaboration. 

Learn how researchers can overcome the challenges inherent in early-phase stability programs and generate high-quality data supporting drug candidate advancement.

Almost every facet of an antibody can be modified. Explore antibody humanization, the importance of affinity and function, isotype selection, and the development of bispecific and antibody-drug conjugates.

Numerous factors impact a drug safety program, but proper management of three key elements highlighted here drives success while creating a scalable drug safety model.

Watch as bioanalytical experts Shane Karnik, MS, and Matt Hartle, Ph.D., explore why many sponsors are reevaluating the use of LBA for large molecule protein analysis in favor of LC-MS.

Witness the widespread adoption of autoinjectors and how they're transforming the biopharmaceutical industry's approach to drug delivery, offering precise dosing, patient adherence, and safety.

With these four steps to successful biologic process development, it is possible to mitigate risk, manufacture a high-quality product, and increase the efficiency of your timeline to patients.

When considering what’s most important in multimodal CDMOs, do organizations truly operate with a customer mindset or prioritize the health and safety of workers and patients?

Here, we look at the results collected when a platform designed with ML-guided GPS engineering was applied to develop a lead molecule targeting a mechanism in neuronal disease.

Discover how knowledge of microbial processes and process characterization understanding can be used to design targeted BLA programs while managing risks.

Discover how CDMOs can help you achieve and maintain CMC compliance throughout the drug development lifecycle. Outsourced Pharma Live will explore how to leverage CDMO expertise in process optimization, documentation, and regulatory submissions. Learn practical strategies to align your CMC goals with CDMO capabilities to accelerate development and ensure successful drug launches. Registration is free thanks to the support of Curia.

We serve more than half of the world’s leading biopharmaceutical companies, sharing their mission to expedite patient access to life-saving biologics.

ÄKTA flux is a semi-automated tangential flow filtration/cross flow filtration system for concentration and diafiltration as well as cell harvest and clarification.

See how our expertise and advanced capabilities provide customized analytical solutions that ensure quality, precision, and regulatory compliance for your biotherapeutics.

We implement a system-wide QbD approach to different phases of a clinical or drug product, including raw materials, in-process, batch release, and stability/shelf-life evaluation.

Lonza Biologics’ end-to-end Drug Product capabilities support the full lifecycle of biologics, seamlessly integrated with their extensive drug substance network across diverse modalities.